Skip to main content

Table 5 Clinical trials of nab-paclitaxel in sarcomas currently recruiting

From: Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma

Title Phase Status Histological subtypes Number of patients Collaborators Dates NCT Number
Nab-paclitaxel and gemcitabine in advanced STS. 1 and 2 Recruiting STS 45 Swiss Group for Clinical Cancer Research Start: October 2018 Completion: October 2022 NCT03524898
Nab-paclitaxel and gemcitabine for recurrent/refractory sarcoma. 2 Recruiting Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, STS 72 H. Lee Moffitt Cancer Center and Research Institute
National Pediatric Cancer Foundation
Start:
October 2016 Completion: March 2021
NCT02945800
Trial of nab-paclitaxel in patients with desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma. 2 Recruiting Desmoid tumors, Desmoplastic small round cell tumors, Ewing sarcoma 61 Grupo Espanol de Investigacion en Sarcomas Start:
May 2017
Completion: September 2020
NCT03275818
Nab-paclitaxel in combination with gemcitabine for pediatric relapsed and refractory solid tumors. 1 Recruiting Dediatric relapsed and refractory solid tumors 24 Emory University, Celgene Corporation Start: August 2018
Completion:
May 2022
NCT03507491
  1. Abbreviations: nab-paclitaxel Albumin-bound paclitaxel, STS Soft tissue sarcoma
\